The Effect of OPCSP on Adherence and Clinical Outcomes Among Patients With Rheumatic Diseases

Sponsor
RenJi Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03024307
Collaborator
(none)
242
1
2
47.4
5.1

Study Details

Study Description

Brief Summary

This is a randomised trial on the efficacy of an Outpatient Pharmacy Clinical Services Program (OPCSP) on adherence and clinical outcomes among patients with rheumatic diseases.The purpose of this study is to evaluate:

  1. rates of medication adherence in the OPCSP program compared with usual care in an integrated health care system.

  2. total direct costs and clinical outcomes in the OPCSP program compared with usual care in an integrated health care system.

Condition or Disease Intervention/Treatment Phase
  • Other: pharmacists involved OPCSP
N/A

Detailed Description

This is a randomised trial on the efficacy of an Outpatient Pharmacy Clinical Services Program (OPCSP) on adherence and clinical outcomes among patients with rheumatic diseases.Three types of rheumatic diseases were included in the study, Systemic lupus erythematosus (SLE), Ankylosing spondylitis (AS), and Rheumatoid Arthritis(RA). The purpose of this study is to evaluate:

  1. rates of medication adherence in the OPCSP program compared with usual care in an integrated health care system.

  2. total direct costs and clinical outcomes in the OPCSP program compared with usual care in an integrated health care system.

Study Design

Study Type:
Interventional
Actual Enrollment :
242 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Evaluation of an Outpatient Pharmacy Clinical Services Program on Adherence and Clinical Outcomes Among Patients With Rheumatic Diseases
Actual Study Start Date :
Jan 18, 2017
Actual Primary Completion Date :
Dec 31, 2020
Actual Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Involvement of pharmacists in improving medication

Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up

Other: pharmacists involved OPCSP
This was an open labelled randomised study. Rheumatic diseases patients were recruited and arbitrarily divided into the intervention group (usual care plus OPCSP) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.

No Intervention: usual care only

Patients were provided with usual care.

Outcome Measures

Primary Outcome Measures

  1. Medication adherence in the OPCSP program compared with usual care [12 months]

    Medication adherence would be evaluated by the questionnaire survey, CQR19. Scores of medication adherence would be calculated.

Secondary Outcome Measures

  1. Changes in medical outcomes from baseline at each visit by EQ5D-3L [12 months]

    The influence of OPCSP on improving medical outcomes would be evaluated by EQ5D-3L. The TTO value would be compared between two arms

  2. changes in direct costs from baseline at each visit [12 months]

    the influence of OPCSP on reducing direct costs

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Willingness of the subject to participate in the study, proven by signing the informed consent;

  • Systemic lupus erythematosus (SLE), as defined by meeting at least 4 of 11 classification criteria of American College of Rheumatology for the classification of systemic lupus erythematosus, either sequentially or coincidentally. The 4 criteria doesn't need to be present at the time of study enrollment;

  • Patients fulfilled the American College of Rheumatology criteria for RA and AS;

Exclusion Criteria:
  • Patients who are unwilling to sign the inform consent;

  • Pregnancy or lactation

Contacts and Locations

Locations

Site City State Country Postal Code
1 South Campus, Ren Ji Hospital Shanghai China 201112

Sponsors and Collaborators

  • RenJi Hospital

Investigators

  • Study Chair: Shuang Ye, MD, RenJi Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ting Li, Doctor, RenJi Hospital
ClinicalTrials.gov Identifier:
NCT03024307
Other Study ID Numbers:
  • OPCSP2016
First Posted:
Jan 18, 2017
Last Update Posted:
Mar 4, 2021
Last Verified:
Jan 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ting Li, Doctor, RenJi Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 4, 2021